Biotechnology
Filter News
Found 46,624 articles
-
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
9/26/2022
Pfizer Inc. and BioNTech SE announced they have completed a submission to the U.S. Food and Drug Administration requesting Emergency Use Authorization of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children 5 through 11 years of age.
-
CellResearch Corporation (CRC) to present promising new stem cell products for the treatment of chronic diabetic foot ulcers at the world's premier diabetic foot conference (DFCon) in Los Angeles
9/26/2022
CRC is delighted to announce attendance at DFCon, the global specialist multidisciplinary congress focused on the diabetic foot held in late September 2022 in Los Angeles, USA.
-
TISSIUM Appoints Sara Toyloy as Independent Board Member
9/26/2022
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has appointed Sara Toyloy as its fourth independent member of the Board of Directors.
-
Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split
9/26/2022
Salt Lake City, Utah--(Newsfile Corp. - September 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that its stockholders authorized a reverse stock split of the Company's common stock.
-
Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference
9/26/2022
Cabaletta Bio, Inc. today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on Monday, October 3, 2022 at 4:00 p.m. ET in New York, NY.
-
Immutep to Participate in Two Upcoming Investor Conferences
9/26/2022
Immutep Limited today announced that Marc Voigt, CEO, and Deanne Miller, COO, will participate in two upcoming investor conferences.
-
Nanoscope Therapeutics to Present at Eyecelerator during the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
9/26/2022
Nanoscope Therapeutics Inc. today announced that Dr. Samarendra Mohanty, Co-Founder and President, will give a presentation on the clinical development of Nanoscope's Multi-Characteristic Opsin (MCO) gene therapy platform at Eyecelerator during the American Academy of Ophthalmology (AAO) 2022 Annual Meeting, taking place Thursday, September 29, 2022, in Chicago, IL.
-
Renovacor Announces Upcoming Presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference
9/26/2022
Renovacor, Inc. (NYSE: RCOR) today announced that preclinical studies characterizing the progression of cardiac dysfunction and mortality in a BAG3 haploinsufficiency mouse model of dilated cardiomyopathy will be featured in an upcoming poster presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference.
-
Clearmind Announces Notice of Proposed Stock Consolidation - September 25, 2022
9/25/2022
Clearmind Medicine Inc., announces that it will be consolidating all of the issued and outstanding common shares of the Company on the basis of one post consolidation Common Share for each thirty pre consolidation Common Shares.
-
Advances in immuno-oncology and adaptive cell therapy that began about a decade ago are enabling fresh, biology-driven approaches to bring therapeutic cancer vaccines closer to fruition.
-
NovoCure announced the launching of a U.S.-based arm to focus on and attempt to grow its glioblastoma (GBM) business and increase its patient population.
-
Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House.
-
This week, researchers delivered insights and breakthroughs in regenerative medicine, Long COVID, immuno-oncology and inflammatory diseases.
-
PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 23, 2022
9/23/2022
PDS Biotechnology Corporation announced PDS Biotech granted nonstatutory stock options to Amber King, PDS Biotech’s Clinical Trial Assistant, to purchase 5,000 shares of PDS Biotech common stock.
-
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer - September 23, 2022
9/23/2022
Tiziana Life Sciences Ltd., a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announces that it has been notified that Matthew Davis, its Chief Medical Officer, purchased 75,000 common shares at $0.83 per share, bringing his total holding to 175,000 common shares.
-
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
9/23/2022
Immutep Limited is pleased to announce it has received a €1,804,341 (~ A$2,693,046 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR).
-
KSQ Therapeutics Announces Leadership and Board Additions
9/23/2022
KSQ Therapeutics today named Micah Benson, PhD as the new Chief Scientific Officer (CSO) and announced the addition of a new Chief Technology Officer (CTO), Tom Leitch, to the KSQ leadership team.
-
Rapid Dose Therapeutics Enters Supplier and Purchase Agreement with a Leading Gas and Convenience Store Retailer for Nutraceutical and Vitamin Products
9/23/2022
Rapid Dose Therapeutics Corp. (“ RDT ” or the “ Company ”) ( CSE: DOSE ), a Canadian biotechnology company focused on health and wellness leveraging an innovative, proprietary oral delivery platform today announced that they have entered into a supplier and purchase agreement with a leading Gas and Convenience Store Retailer.
-
Caris Life Sciences and Flatiron Health Partner to Vastly Increase Access to Most Comprehensive Molecular Testing Available
9/23/2022
Caris Life Sciences® announced a partnership with Flatiron Health, a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients, to integrate Caris' market leading molecular testing portfolio with OncoEMR®, a leading cloud-based electronic medical record tool.
-
AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer
9/23/2022
AlivaMab Discovery Services, a leader in the discovery of superior antibody-based therapeutics, announced that Larry Green has reassumed the role of Chief Executive Officer, effective immediately.